LncRNA TUG1 contributes to cardiac hypertrophy via regulating miR-29b-3p

  • Xue Zou
  • Jialiang Wang
  • Li Tang
  • Qian WenEmail author


Cardiac hypertrophy with maladjusted cardiac remodeling is the leading cause of heart failure. In the past decades, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been proved to exert multiple functions in cellular biological behaviors; however, their role in cardiac hypertrophy remains largely unclear. Presently, we first obtained hypertrophic H9c2 cells by treating with angiotensin II (Ang II) and uncovered upregulation of lncRNA taurine upregulated gene 1 (TUG1) in such H9c2 cells. Then, we demonstrated that silencing TUG1 attenuated Ang II–induced cardiac hypertrophy. Besides, a strong interactivity of TUG1 with miR-29b-3p at the putative sites was validated, suggesting that TUG1 was an endogenous sponge of miR-29b-3p in H9c2 cells. Additionally, the expression of miR-29b-3p was strikingly reduced by TUG1 upregulation and also inhibited under Ang II treatment, whereas it was restored after silencing TUG1 in hypertrophic cells. Also, we proved miR-29b-3p as a negative regulator in cardiac hypertrophy. Finally, miR-29b-3p inhibition abolished the anti-hypertrophy effect of TUG1 depletion in Ang II–treated H9c2 cells. Collectively, our findings confirmed that TUG1 functioned as a positive modulator of cardiac hypertrophy via sponging miR-29b-3p, indicating that TUG1 might serve as a potential target for the treatment of cardiac hypertrophy and even heart failure.


TUG1 miR-29b-3p Ang II Cardiac hypertrophy H9c2 cells 



Thank you for all the participators.


This work was funded by the role of GRK4 methylation in the hypertension induced by pregnancy cold-exposure.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.


  1. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128:191–227CrossRefGoogle Scholar
  2. Cai H, Xue Y, Wang P, Wang Z, Li Z, Hu Y, Li Z, Shang X, Liu Y (2015) The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. Oncotarget 6:19759–19779Google Scholar
  3. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613–618CrossRefGoogle Scholar
  4. Chen L (2017) MiR-29b-3p promotes chondrocyte apoptosis and facilitates the occurrence and development of osteoarthritis by targeting PGRN, vol 21, pp 3347–3359Google Scholar
  5. Diwan A, Dorn GW 2nd (2007) Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 22:56–64Google Scholar
  6. Drummond C, Hill M, Shi H, Fan X, Xie J, Haller S, Kennedy D, Liu J, Garrett M, Xie Z, Cooper C, Shapiro J, Tian J (2016) Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts. Physiol Genomics 48:220–229CrossRefGoogle Scholar
  7. Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45–79CrossRefGoogle Scholar
  8. Han D, Gao Q, Cao F (2017) Long noncoding RNAs (LncRNAs) - the dawning of a new treatment for cardiac hypertrophy and heart failure. Biochim Biophys Acta 1863:2078–2084CrossRefGoogle Scholar
  9. Jiang N, Xia J, Jiang B, Xu Y, Li Y (2018) TUG1 alleviates hypoxia injury by targeting miR-124 in H9c2 cells. Biomed Pharmacother 103:1669–1677CrossRefGoogle Scholar
  10. Jiang W, Zhang Z, Yang H, Lin Q, Han C, Qin X (2017) The involvement of miR-29b-3p in arterial calcification by targeting matrix metalloproteinase-2. Biomed Res Int 2017Google Scholar
  11. Kakimoto Y, Tanaka M, Hayashi H, Yokoyama K, Osawa M (2018) Overexpression of miR-221 in sudden death with cardiac hypertrophy patients. Heliyon 4:e00639CrossRefGoogle Scholar
  12. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D (2013) Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2:e000078CrossRefGoogle Scholar
  13. Karapetyan AR, Buiting C, Kuiper RA, Coolen MW (2013) Regulatory roles for long ncRNA and mRNA. Cancers (Basel) 5:462–490CrossRefGoogle Scholar
  14. Klinge CM (2018) Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer 25:R259–R282CrossRefGoogle Scholar
  15. Leistner DM, Boeckel J-N, Reis SM, Thome CE, De Rosa R, Keller T, Palapies L, Fichtlscherer S, Dimmeler S, Zeiher AM (2016) Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics. Eur Heart J 37:1738–1749CrossRefGoogle Scholar
  16. Li C, Zhou G, Feng J, Zhang J, Hou L, Cheng Z (2018) Upregulation of lncRNA VDR/CASC15 induced by facilitates cardiac hypertrophy through modulating miR-432-5p/TLR4 axis. Biochem Biophys Res Commun 503:2407–2414. CrossRefGoogle Scholar
  17. Liu L, An X, Li Z, Song Y, Li L, Zuo S, Liu N, Yang G, Wang H, Cheng X, Zhang Y, Yang X, Wang J (2016) The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc Res 111:56–65CrossRefGoogle Scholar
  18. Liu Q, Liu H, Cheng H, Li Y, Li X, Zhu C (2017) Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells. Onco Targets Ther 10:2461–2471CrossRefGoogle Scholar
  19. Long J, Menggen Q, Wuren Q, Shi Q, Pi X (2018) Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes tumor growth and metastasis through TUG1/Mir-129-5p/astrocyte-elevated gene-1 (AEG-1) axis in malignant melanoma. Med Sci Monit 24:1547–1559CrossRefGoogle Scholar
  20. Lv L, Li T, Li X, Xu C, Liu Q, Jiang H, Li Y, Liu Y, Yan H, Huang Q, Zhou Y, Zhang M, Shan H, Liang H (2018) The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. Mol Ther Nucleic Acids 10:387–397CrossRefGoogle Scholar
  21. Marques F, Vizi D, Khammy O, Mariani J, Kaye D (2016) The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail 18:1000–1008CrossRefGoogle Scholar
  22. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10:155–159CrossRefGoogle Scholar
  23. Rainer J, Meraviglia V, Blankenburg H, Piubelli C, Pramstaller PP, Paolin A, Cogliati E, Pompilio G, Sommariva E, Domingues FS, Rossini A (2018) The arrhythmogenic cardiomyopathy-specific coding and non-coding transcriptome in human cardiac stromal cells. BMC Genomics 19:491CrossRefGoogle Scholar
  24. Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, Pagano F, Schiavon S, Bordin A, Carrizzo A, Vecchione C, Valenti V, Chimenti I, De Falco E, Sciarretta S, Frati G (2017) A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxidative Med Cell Longev 2017:3920195CrossRefGoogle Scholar
  25. Shao M, Chen G, Lv F, Liu Y, Tian H, Tao R, Jiang R, Zhang W, Zhuo C (2017) LncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII. Oncotarget 8:47565–47573Google Scholar
  26. Shen S, Jiang H, Bei Y, Xiao J, Li X (2017) Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem 41:1830–1837CrossRefGoogle Scholar
  27. Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L, Gao W, Sun Y (2018) The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med 22:3847–3856. CrossRefGoogle Scholar
  28. Tay Y, Rinn J, Pandolfi PP (2014) The multilayered complexity of ceRNA crosstalk and competition. Nature 505:344–352CrossRefGoogle Scholar
  29. Thum T, Condorelli G (2015) Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res 116:751–762CrossRefGoogle Scholar
  30. Tu J, Zhao Z, Xu M, Lu X, Chang L, Ji J (2018) NEAT1 upregulates TGF-beta1 to induce hepatocellular carcinoma progression by sponging hsa-mir-139-5p. J Cell Physiol 233:8578–8587. CrossRefGoogle Scholar
  31. Wang Q, Chen Q (2018) Role of taurine upregulated gene 1 as a predictor of poor outcome in osteosarcoma. J Cancer Res Ther 14:405–409CrossRefGoogle Scholar
  32. Wang RY, Rudser KD, Dengel DR, Braunlin EA, Steinberger J, Jacobs DR, Sinaiko AR, Kelly AS (2017) The carotid intima-media thickness and arterial stiffness of pediatric Mucopolysaccharidosis patients are increased compared to both pediatric and adult controls. Int J Mol Sci 18Google Scholar
  33. Widlansky ME (2018) miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. 10Google Scholar
  34. Xu Y, Deng W, Zhang W (2018) Long non-coding RNA TUG1 protects renal tubular epithelial cells against injury induced by lipopolysaccharide via regulating microRNA-223. Biomed Pharmacother 104:509–519CrossRefGoogle Scholar
  35. Yang B, Tang X, Wang Z, Sun D, Wei X, Ding Y (2018) TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a. Biosci Rep 38:BSR20180677. CrossRefGoogle Scholar
  36. Yang T, Gu H, Chen X, Fu S, Wang C, Xu H, Feng Q, Ni Y (2014) Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo. J Surg Res 192:317–325CrossRefGoogle Scholar
  37. Zhu X, Yuan Y, Rao S, Wang P (2016) LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci 20:3653–3660Google Scholar
  38. Zhu Y, Feng Z, Jian Z, Xiao Y (2018a) Long noncoding RNA TUG1 promotes cardiac fibroblast transformation to myofibroblasts via miR-29c in chronic hypoxia. Mol Med Rep 18:3451–3460Google Scholar
  39. Zhu YFZ, Jian Z, Xiao Y (2018b) Long noncoding RNA TUG1 promotes cardiac fibroblast transformation to myofibroblasts via miR-29c in chronic hypoxia. Mol Med Rep 35:29–36Google Scholar

Copyright information

© The Society for In Vitro Biology 2019

Authors and Affiliations

  1. 1.Department of CardiologyDaping Hospital, The Third Military Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations